ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026
Translation of Intraoperative Molecular Imaging for Clinical Use.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Intraoperative molecular imaging (IMI) is an evolving tool that enables targeted real-time visualization and delineation of tissue during surgery. IMI tracers can be fluorescent, radioactive, or dual-labeled. Their integration into the intraoperative setting is supported by several clinical trials, which led to Food and Drug Administration approval for a variety of these agents. Fluorescent tracers enable excellent spatial visualization, whereas radiotracers enable deep tissue detection, and dual-labeled tracers provide both. Novel activatable tracers that leverage properties of the tumor microenvironment are also being developed. Advances in imaging devices now permit IMI usage across diverse platforms, including minimally invasive surgery. Despite the limitations of autofluorescence, false-positive signals, and heterogeneity, the use of IMI continues to broaden in oncologic and nononcologic applications, driven by demonstrated improvements in surgical outcomes. In this review, we highlight the translation of IMI through clinical trials and future directions in IMI-guided surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.